Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P80098 (
monocyte chemoattractant protein
)
1,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
HIV-infected patients are at increased risk of decreased bone mineral density. Several studies have implicated antiretroviral therapy as a contributor to the decreased bone mineral density seen in treated HIV-1 patients. Whilst the exact molecular mechanisms underlying decreased bone density remain to be elucidated, inflammation has been postulated to be an important pathogenomic mechanism. In this study, we have explored primary human osteoblast gene expression in response to protease inhibitors (PIs), by oligonucleotide microarray analysis. A list of dysregulated genes, correlated with the inflammatory response, increased significantly after
NFV
and RTV exposure. Analysis of gene and protein expression determined a selectively increase of the pro-inflammatory cytokines
monocyte chemoattractant protein
(
MCP
)-1 and interleukin-8 (IL-8) following exposure to a pharmacological concentration of
NFV
and RTV. These data suggested that generation of local inflammatory cascades may contribute to the development of decreased bone mineral density in highly active antiretroviral therapy (HAART)-treated HIV patients.
...
PMID:HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. 1724 Apr 60